Literature DB >> 15266289

[Genetic and microbiologic tests in periodontal disease].

L Checchi1, M R Gatto, A Pattison, P Felice.   

Abstract

AIM: The presence of genetic polymorphisms IL-1A and IL-1B was demonstrated to be associated to an increased clinical severity of Periodontitis. The aim of our study was to verify the existence of a relationship between such genetic polymorphisms and pathogenic variations of Actinobacillus actinomycetemcomitans (Aa), Prevotella intermedia (Pi) and Porphyromonans gingivalis (Pg), in patients with periodontitis before and after active therapy.
METHODS: Twenty-five patients were randomly selected among those attending the Department of Periodontology, University of Bologna, on the basis of radiographic and clinical data. At the end of active therapy, subjects had to undergo "PST" test.
RESULTS: The "PST" was positive in 32% (8 out of 25) of patients; the majority of them (4 out of 8) were classified ADA IV, 3 were ADA III and 1 was ADA I (p > 0.05). All subjects with good hygiene therapy (13 out of 24 patients) have shown a reduced bacterial count after active clinical therapy (Fisher test p = 0.03).
CONCLUSION: No statistically significant association was observed between positivity to "PST" and severity of periodontal disease.

Entities:  

Mesh:

Year:  2004        PMID: 15266289

Source DB:  PubMed          Journal:  Minerva Stomatol        ISSN: 0026-4970


  2 in total

Review 1.  The Association between Tooth Loss and Alzheimer's Disease: a Systematic Review with Meta-Analysis of Case Control Studies.

Authors:  Mario Dioguardi; Giovanni Di Gioia; Giorgia Apollonia Caloro; Giorgia Capocasale; Khrystyna Zhurakivska; Giuseppe Troiano; Lucio Lo Russo; Lorenzo Lo Muzio
Journal:  Dent J (Basel)       Date:  2019-05-01

2.  Periodontal infectogenomics: a systematic review update of associations between host genetic variants and subgingival microbial detection.

Authors:  Noha Zoheir; Yuko Kurushima; Guo-Hao Lin; Luigi Nibali
Journal:  Clin Oral Investig       Date:  2022-02-05       Impact factor: 3.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.